CATB Insider Trading Activity and SEC Form 4 Filings
CATB insider trading summary
No open-market insider purchases or sales of Catabasis Pharmaceuticals Inc (CATB) have been reported on SEC Form 4 in the past 12 months.
Latest CATB insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 30, 2015 | Ron Laufer | Director | Buy | $2.7M (223,439 @ $12.00) |
| Jun 30, 2015 | Sv Life Sciences Fund V LP | 10% Owner | Buy | $97K (8,094 @ $12.00) |
| Jun 30, 2015 | MedImmune Ventures, Inc. | 10% Owner | Buy | $2.7M (223,439 @ $12.00) |
| Jun 30, 2015 | Nicholas Galakatos | Director | Buy | $4.5M (376,695 @ $12.00) |
| Jun 30, 2015 | Jean George | Director | Buy | $149K (12,422 @ $12.00) |
| Jun 30, 2015 | Jean George | Director | Buy | $1.1M (91,166 @ $12.00) |
| Jun 30, 2015 | Jean George | Director | Buy | $1.9M (155,188 @ $12.00) |
| Jun 30, 2015 | Clarus Lifesciences II, L.P. | 10% Owner | Buy | $4.5M (376,695 @ $12.00) |
| Jun 30, 2015 | Clarus Ventures II, LLC | 10% Owner | Buy | $4.5M (376,695 @ $12.00) |
| Jun 30, 2015 | Clarus Ventures II GP, L.P. | 10% Owner | Buy | $4.5M (376,695 @ $12.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.